Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review

Abstract

There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.

Extracellular Vesicles and Their Zeta Potential as Future Markers Associated with Nutrition and Molecular Biomarkers in Breast Cancer

“…We excluded the fat mass index variable, to avoid collinearity with weight and visceral fat. On the multivariate model, we decided to include the variables of molecular classification of the tumor, ER positive, and LDL cholesterol due to their previously reported association with the expression of miRNA-155 [ 38 ] and fat mass in patients with breast cancer; additionally, we included variables whose p -value was close to 0.2 ( Table 2 ). The multivariate model showed that visceral fat (negative) and Ki67 (positive) were significant, and when combined, they formed the best association model ( Table 3 ).…”

miRNA-Based Therapeutics in Breast Cancer: A Systematic Review

“…To date, just a few miR-based therapeutics are actually under Phase-I clinical trials for oncological diseases (see Table 3 ), such as Cobomarsen and TargomiR, both developed by miRagen Therapeutics. Cobomarsen, (also known as MRG-106) is an inhibitor of miR-155, an oncomir highly expressed in a wide range of cancers, including BC ( 44 ). Two clinical trials are ongoing in Phase I, to evaluate the safety of this drug for the treatment of adult patients diagnosed with certain lymphomas and leukemias (NCT02580552 and NCT03713320).…”

Poly-antioxidants for enhanced anti-miR-155 delivery and synergistic therapy of metastatic breast cancer

“…It has been reported in the literature that the overexpression of miR-155 could be a diagnostic target for breast cancer. 29 It suggests that the delivery of the miR-155 inhibitor (anti-miR-155) may hold the potential for breast cancer therapy. We firstly evaluated the transfection efficiency of anti-miR-155 loaded polyplexes in 4T1 cell lines.…”